Home / MissionIR Articles / Provectus Pharmaceuticals, Inc. (PVCT) Starts Presentation at LD Micro Conference

Provectus Pharmaceuticals, Inc. (PVCT) Starts Presentation at LD Micro Conference

Provectus Pharmaceuticals specializes in developing oncology and dermatology therapies. The company’s oncology drug PV-10 is designed to target and destroy cancer cells without harming surrounding healthy tissue while its dermatological drug PH-10 targets abnormal or diseased cells. Provectus recently completed phase 2 clinical trials of PV-10 as a therapy for metastatic melanoma and of PH-10 as a topical treatment for atopic dermatitis and psoriasis. For more information, visit the company’s website at www.pvct.com.